Clinical Gastroenterology and Hepatology · Oct 31, 2026
Development and validation of the OpENS model for upper gastrointestinal cancer screening across diverse regions in China
By Sun K, Zheng R, Dou L et al.
BACKGROUND & AIMS: The application and performance of upper gastrointestinal (UGI) cancer risk stratification tools across diverse regions in China remains unclear. We aimed to develop decision-making tools for personalized screening adapted to different regions. METHODS: Participants were recruited from 386 hospitals in 2023 and followed up to December 2025. Individuals with advanced neoplasias in the esophagus, cardia and non-cardiac gastric region (NCGR) confirmed during screening, and UGI cancer patients identified within a six-month period, were counted as advanced neoplasia cases. Participants were grouped into new (NP) and returning patients (RP) according to prior history of UGI endoscopy. Individual risk factors were collected and multivariate models were constructed and externally validated. A risk score was calculated using decile ranking of the model scores. Regions were categorized into high-, medium-, and low-risk based on local UGI cancer incidence. The ratio of the number needed to screen (NNS) between universal and high-risk individual screening was calculated to evaluate efficiency improvement. RESULTS: 17,688 (2.63%) UGI advanced neoplasia cases were confirmed in 673,126 participants. The AUCs of the multivariate models exceeded 0.850 for esophagus and cardia, and 0.750 for NCGR. For individual risk assessment, the optimal risk score screening threshold was 8, yielding a 2.3-fold efficiency gain. For regional screening strategies, the optimal screening threshold was 1 for NPs and 5 for RPs in high-risk regions, 3 for NPs and 6 for RPs in medium-risk regions, and 6 for NPs and 8 for RPs in low-risk regions. This yielded 1.02-, 1.19- and 2.07-fold efficiency gain in each region, respectively. CONCLUSIONS: The risk stratification model can be readily implemented and increases the efficiency of opportunistic UGI cancer screening across diverse regions in China.
doi.org/10.1016/j.cgh.2026.10.018Open accessPubMed 42966458Biomarkers